NSE › Basic Materials

Tatva Chintan Pharma Chem Limited (TATVA)

NSE · Basic Materials · Specialty Chemicals

₹1,709.60+3.81%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

₹167 cr

Revenue YoY

+42.9%

Net profit

₹16 cr

Profit YoY

+140.3%

EPS

₹7.26

EPS estimate

₹6.05

Net margin

9.6%

EPS came in at 7.26 against a street estimate of 6.05 — a beat of 19.9%.

Key statistics

Market cap

₹3,763 cr

P/E

73.0

Forward P/E

0.0

P/B

4.96

Book value

₹334.03

EPS (TTM)

₹22.04

52-week high

₹1,835.89

52-week low

₹980.31

50-day MA

₹1,613.20

200-day MA

₹1,332.99

Beta

0.29

Analyst view

with an average price target of ₹1,442.50.

Shareholding

Promoters

74.16%

Institutions

5.82%

Recent filings & reports

Document	Date
Annual report FY2026 TATVA CHINTAN PHARMA CHEM LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹4,962.96 million (FY 2025-26) vs ₹3,664.15 milli	2026-08-27
Q1 FY27 earnings call TATVA CHINTAN PHARMA CHEM LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Operating revenue: INR 1,671 million in Q1 FY27, up 43% year-on-year and 25%	2026-07-21
Investor presentation · Q1 FY27 TATVA CHINTAN PHARMA CHEM LIMITED - Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: ₹1,671 Mn, up 43% YoY (Q1 FY26: ₹1,169 Mn) • Q1 FY2	2026-07-17
Quarterly results · Q1 FY27 TATVA CHINTAN PHARMA CHEM LIMITED – INVESTOR SUMMARY Q1 FY2026-27 Results (Quarter ended 30 June 2026) --- HEADLINE NUMBERS CONSOLIDATED RESULTS (Q	2026-07-17
Q4 FY26 earnings call TATVA CHINTAN PHARMA CHEM LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 Operating Revenue: INR 1,341 million – 24% YoY growth, 2% QoQ growth	2026-05-19
Investor presentation · Q4 FY26 TATVA CHINTAN PHARMA CHEM LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue from Operations: ₹5,059 Mn (up 32% YoY from ₹3,827 Mn in FY25)	2026-05-16
Quarterly results · Q4 FY26 TATVA CHINTAN PHARMA CHEM LIMITED — INVESTOR SUMMARY HEADLINE NUMBERS • Revenue from operations (FY 2025-26): Rs 5,058.58 million • Net profit after	2026-05-16
Q3 FY26 earnings call TATVA CHINTAN PHARMA CHEM LIMITED – Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY2026 Operating Revenue: INR 1,313 million (53% YoY growth, 6% sequentia	2026-01-24

Readable in the app.

Corporate actions

Action	Detail	Date
Dividend	₹2 / share ex-date Sep 11, 2026	2026-09-11
Dividend	₹1 / share ex-date Sep 12, 2025	2025-09-12

Deals & corporate news

Announcement	Date
Capacity addition announced for manufacturing operations Tatva Chintan Pharma Chem Limited has informed the Exchange about Capacity addition	2026-07-17
Acquisition announced Tatva Chintan Pharma Chem Limited has informed the Exchange about Acquisition	2026-02-18

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tatva Chintan Pharma Chem Limited — free to start.

Google Play App Store

Other Basic Materials companies

UltraTech Cement Limited JSW Steel Limited Hindustan Zinc Limited Asian Paints Limited Tata Steel Limited Grasim Industries Limited Hindalco Industries Limited Solar Industries India Limited VEDANTA ALUMINIUM METAL LTD Pidilite Industries Limited Jindal Steel & Power Limited LLOYDS METALS AND ENERGY LTD.

Data updated 2026-09-18.